Cell & Gene Therapy

FDA Meetings: Engaging Regulators Throughout Cell and Gene Therapy Development

Download Now
FDA Meetings: Engaging Regulators Throughout Cell and Gene Therapy Development

Learn how sponsors can strategically engage with the FDA throughout cell and gene therapy development to reduce risk, strengthen development plans, and accelerate progress toward commercialization.

 

Watch the Trailer:



Session Overview

Cell and gene therapies present unique development challenges, from novel manufacturing processes and delivery approaches to complex nonclinical programs and evolving regulatory expectations. Early and effective FDA engagement can help sponsors clarify development requirements, identify potential issues, and establish a more efficient path toward clinical development and commercialization.

In this webinar, Premier Research experts discuss FDA meeting opportunities available throughout cell and gene therapy development, including INTERACT, Pre-IND, Type D, and Pre-BLA meetings. The session explores when each meeting may be appropriate, how to prepare effective meeting requests and briefing packages, and strategies for addressing regulatory feedback when discussions do not go as planned.

What You’ll Learn:

  • How to align INTERACT, Pre-IND, Type D, and Pre-BLA meetings with your program’s stage and development objectives
  • Best practices for preparing meeting requests, briefing packages, and focused questions
  • Strategies for navigating FDA feedback and responding to challenges following an unsatisfactory Pre-IND meeting
  • How proactive regulatory engagement can support more efficient development decisions

Complete the form to watch the session on demand.

Ready to get started? So are we.

Drop us a line to learn more about how we can help.